In the past week, NNNN stock has gone up by 14.90%, with a monthly gain of 31.96% and a quarterly surge of 44.20%. The volatility ratio for the week is 4.89%, and the volatility levels for the last 30 days are 2.93% for Anbio Biotechnology The simple moving average for the past 20 days is 19.96% for NNNN’s stock, with a 39.45% simple moving average for the past 200 days.
Is It Worth Investing in Anbio Biotechnology (NASDAQ: NNNN) Right Now?
Anbio Biotechnology (NASDAQ: NNNN) has a higher price-to-earnings ratio of 164.19x compared to its average ratio.
The public float for NNNN is 39.69M, and currently, short sellers hold a 0.06% ratio of that float. The average trading volume of NNNN on June 18, 2025 was 61.62K shares.
NNNN) stock’s latest price update
The stock of Anbio Biotechnology (NASDAQ: NNNN) has increased by 10.43 when compared to last closing price of 9.01.Despite this, the company has seen a gain of 14.90% in its stock price over the last five trading days. globenewswire.com reported 2025-05-15 that Accelerating Expansion Across Human and Veterinary Health Through Innovation and Strategic Collaboration Accelerating Expansion Across Human and Veterinary Health Through Innovation and Strategic Collaboration
NNNN Trading at 36.17% from the 50-Day Moving Average
After a stumble in the market that brought NNNN to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 7.68% of gains for the given period.
Stock Fundamentals for NNNN
Current profitability levels for the company are sitting at:
- 0.24 for the present operating margin
- 0.72 for the gross margin
The net margin for Anbio Biotechnology stands at 0.29. The total capital return value is set at 0.13. Equity return is now at value 15.00, with 13.83 for asset returns.
Currently, EBITDA for the company is 2.57 million with net debt to EBITDA at -4.59. When we switch over and look at the enterprise to sales, we see a ratio of 48.01. The receivables turnover for the company is 8.31for trailing twelve months and the total asset turnover is 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.71.
Conclusion
To put it simply, Anbio Biotechnology (NNNN) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
